College of Medicine, The Ohio State University, Columbus, USA.
Division of Sports Medicine, Department of Orthopaedics, Wexner Medical Center, OSU Sports Medicine Center, The Ohio State University, 2050 Kenny Road, Suite 3100, Columbus, OH, 43221, USA.
Knee Surg Sports Traumatol Arthrosc. 2020 Nov;28(11):3539-3550. doi: 10.1007/s00167-020-06058-6. Epub 2020 May 15.
When compared to meniscectomy, meniscus allograft transplantation (MAT) may provide superior long-term benefits to young, active patient populations who have lost meniscal function because of irreparable damage, such as, an avascular tear, previous repair failure, and unsalvageable tear types. Positive outcomes are most likely to be achieved when meniscus allograft transplantation is performed in appropriately selected patients. Indications include patients younger than 50 years of age, with a history of subtotal or total meniscectomy without concomitant articular cartilage defects, uncorrectable joint malalignment, and/or knee instability. Outcomes for meniscal allograft transplantation are promising with studies reporting long-term graft survivorship as high as 89% at 10 years and significant improvements in multiple patient reported outcome measures. LEVEL OF EVIDENCE: Level V.
与半月板切除术相比,半月板同种异体移植(MAT)可能为因不可逆转的损伤而丧失半月板功能的年轻、活跃的患者群体提供更好的长期获益,这些损伤包括无血管撕裂、先前修复失败和不可挽救的撕裂类型。当在适当选择的患者中进行半月板同种异体移植时,最有可能获得阳性结果。适应证包括年龄小于 50 岁、有半月板部分或全部切除术病史但无伴发关节软骨缺损、不可矫正的关节对线不良和/或膝关节不稳定的患者。半月板同种异体移植的结果很有前景,研究报告称,10 年时的长期移植物存活率高达 89%,并且多项患者报告的结果测量指标有显著改善。证据等级:5 级。